

Curriculum Vitae
LAURA PASQUALUCCI, M.D.

EDUCATION

1991 University of Perugia School of Medicine
M.D., *Summa Cum Laude*
1991-1995 University of Perugia School of Medicine
Residency in Hematology, *Summa Cum Laude*

POST DOCTORAL TRAINING

4/2000-9/2001 Post-doctoral Research Scientist
Molecular Genetics of Lymphoma (Dr. Riccardo Dalla-Favera)
Institute for Cancer Genetics and the Department of Pathology
Columbia University, New York, NY

4/1997-3/2000 Post-doctoral Research Fellow
Molecular Genetics of Lymphoma (Dr. Riccardo Dalla-Favera)
Institute for Cancer Genetics and the Department of Pathology
Columbia University, New York, NY

2/1996-3/1997 Visiting Research Fellow
Molecular Pathology of Lymphoma
Institute of Pathology (Prof. Harald Stein)
Universitätsklinikum B. Franklin, Freie Universität Berlin, Germany

11/1991-11/1995 Resident Physician, Institute of Hematology and Bone Marrow
Transplantation Unit
University of Perugia Medical School, Perugia, Italy

ACADEMIC APPOINTMENTS

2008-present Associate Professor of Pathology & Cell Biology at CUMC
(in the Institute for Cancer Genetics)
Columbia University, New York, NY

2001-2008 Assistant Professor of Clinical Pathology & Cell Biology
(in the Institute for Cancer Genetics)
Columbia University, New York, NY

2008-present Associate Professor of Hematology (MED/15)
Institute of Hematology and Clinical Immunology
Department of Clinical and Experimental Immunology
University of Perugia Medical School, Perugia, Italy

PROFESSIONAL ORGANIZATIONS, SOCIETIES AND SERVICES

Memberships and Positions

2014- American Association for Cancer Research
2010- American Society of Hematology
1993- Italian Society of Experimental Hematology

Consultative

2014-present Lymphoma Research Foundation: Grant Oversight Committee
2013-present Lymphoma Research Foundation: Scientific Advisory Board
2016 NIH Special Emphasis Panel F09A-D Fellowships Oncology: Reviewer
2016 ASH Meeting in Lymphoma Biology Steering Committee
2015-2016 AACR Millennium Fellowships: Scientific Review Committee
2015-2016 Leukemia and Lymphoma Society, SCOR Grants: Review Committee
2015-2016 Leukemia and Lymphoma Society, CDP Grants: Review Committee
2015 NIH Special Emphasis Panel F09A-D Fellowships Oncology, July 20-21: Reviewer
2014 NIH/NCI Developmental Therapeutics Study Section February 23-24: ad hoc Reviewer
2014-2015 AACR Millennium Fellowships, Scientific Review Committee
2014-2015 Leukemia and Lymphoma Society, SCOR program: Grants Review Committee
2014 Ludwig Boltzmann Gesellschaft, Vienna, Austria: Grants Evaluation Committee
2014 NIH/NCI Developmental Therapeutics Study Section June 19-20: ad hoc Reviewer
2014 NIH/NCI Special Emphasis Panel Epidemiology of Cancer, March 7: hoc Reviewer
2013 NIH/NCI Cancer Screening and Biomarker ZCA1RPRB-7(O1) S (R03, R21): Reviewer

2012 NIH/NCI Special Emphasis Panels Training Grants (K01, K12) Nov5: ad hoc Reviewer
2012 NIH/NCI SPORE PROGRAM September 19-20: Peer Review Committee
2012 NIH/NCI SPORE PROGRAM February 8-9: Peer Review Committee
2012- Leukemia and Lymphoma Research UK – Grants Reviewer
2011- Cancer Research UK – Training & Career Development Grant – Grants Reviewer
2010 Kay Kendall Leukaemia Fund – Junior Fellowship Applications – Grants Reviewer
2009-2013 Lymphoma Research Foundation- Panel of Scientific Advisors
2008 Austrian Science Fund (FWF) – Grants Reviewer
2008 Institut National Du Cancer, Lymphoma Program, France – Reviewer

Editorial

2015 Editor: Malignant Lymphomas: Biology and Molecular Pathogenesis, *De Gruyter (pub)*
2009-2014 Editorial Board: *Blood*

- 2007-present Ad hoc Reviewer: *Nature, Nature Genetics, Nature Immunology, Nature Medicine, New Engl J Med, Science, Cancer Cell, Proc. Natl Acad Sci USA, J Exp Med, Journal of Clinical Investigation, Cell Reports, Blood, Clinical Cancer Research, Cancer Research, Haematologica, Br J Hematology, J Pathology, Experimental Hematology, Hematol Oncol, Acta Haematologica*
- 1999-present Ad hoc Reviewer: *Blood, Leukemia*

SELECTED INVITED LECTURES at INTERNATIONAL MEETINGS (past 5 years)

- February 2011 7th Annual Hematological Malignancies Symposium
Hollings Cancer Center of the Medical University of South Carolina
- June 2011 16th Congress of the European Haematology Association
London, England
- October 2011 UK Lymphoma Trials Meeting
Mike Bennet Guest Lecture
London, United Kingdom
- May 2012 Herbert Irving Comprehensive Cancer Center Annual Symposium
Epigenetics and Cancer
Columbia University, New York, NY
- May 2012 Fifth International Conference on Innovative Therapies for Lymphoid
Malignancies
Palermo, Italy
- October 2012 XII Congresso Nazionale SIES (Italian Society of Experimental Hematology)
Roma, Italia
- November 2012 Fourth International Symposium on Childhood, Adolescent and Young Adult
Non-Hodgkin's Lymphoma
New York, NY
- April 2013 10th International Chicago Lymphoma Symposium
Chicago, IL
- June 2013 18th Congress of the European Haematology Association
Molecular Hemopoiesis Workshop
Stockholm, Sweden
- June 2013 12th International Conference on Malignant Lymphoma
Closed Workshop on Diffuse Large B cell Lymphoma
Lugano, Switzerland
- August 2013 FASEB Research Conferences – Hematologic Malignancies
Saxtons Rivers, MA
- August 2014 American Society of Hematology Meeting on Lymphoma Biology
Colorado Springs, CO
- September 2014 American Association for Cancer Research

	Special Conference on Hematologic Malignancies Translating Discoveries to Novel Therapies Philadelphia, PA
December 2014	American Society of Hematology Annual Meeting Scientific Committee on Lymphoid Neoplasia San Francisco, CA
April 2015	American Association for Cancer Research Annual Meeting Philadelphia, PA
June 2015	13th International Conference on Malignant Lymphoma Closed Workshop on Follicular Lymphoma Lugano, Switzerland
October 2015	British Lymphoma Pathology Group Annual Meeting <i>Keynote lecture</i> Cambridge, UK
October 2015	Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's Lymphoma Varese, Italy
May 2016	First Nordic Meeting on Tumor Microenvironment in Lymphoma: Biology and Targeting Strategy Copenhagen, Denmark
May 2016	Memorial Sloan Kettering Symposium on Lymphoma State of the art in biology, therapy and patient care New York, NY
June 2016	American Society of Hematology Meeting on Lymphoma Biology Colorado Springs, CO
June 2016	Berlymphoma Meeting on Lymphoid Malignancies Berlin, Germany
November 2016	Fifth International Conference on Innovative Therapies for Lymphoid Malignancies Palermo, Italy

TEACHING EXPERIENCE AND RESPONSIBILITIES

Annual Courses

2015-2016	Cellular and Molecular Biology of Cancer, Pathology G4500 Lymphoma as a Cancer Model Columbia University, New York, NY
2012-2015	European School of Oncology and Ulm University Certificate of Competence in Lymphoma (CCL) program Oncogenes and Tumor Suppressor Genes
2011-2015	Molecular Pathogenesis of Hematologic Malignancies

- 2006-2011 University of Perugia Medical School, Perugia, Italy
Cellular and Molecular Biology of Cancer, Pathology G4500
Lymphoma as a Cancer Model
Columbia University, New York, NY
- 2003-2006 Molecular Pathogenesis of Non-Hodgkin Lymphoma
University of Perugia Medical School, Perugia, Italy

PhD/Master Theses Trainees

- 2008- Integrated PhD Program in Cellular, Molecular and Biophysical Studies
Columbia University, New York, NY

Ph.D. Examination-, Advisory-, and Defense Committee

- 2015- Integrated PhD Program in Cellular, Molecular and Biomedical Studies
Columbia University (C2B2 Special Track)
Thesis Examination Committee
- 2012- PhD Program in Pathobiology and Molecular Medicine, Columbia University
Thesis Examination Committee
- 2013 PhD Program in Pharmacology and Molecular Signaling, Columbia University
Thesis Examination Committee
- 2012-2014 Fellowship Scholarly Oversight Committee, Columbia University
Divisions of Pediatric Hematology, Blood and Marrow Transplantation
- 2008-2010 Fellowship Scholarly Oversight Committee, Columbia University
Divisions of Pediatric Hematology, Blood and Marrow Transplantation

Other Trainee Advisory Roles

- 2000-present Advisor of post-doctoral fellows, visiting scientists and student trainees

PUBLICATIONS

Original, Peer Reviewed Articles (in chronological order):

1. Georgiou K, Chen L, Berglund L, Ren W, de Miranda N, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, Fang W, Wang X, Meng B, Zhang L, Zeng L, Bhagat G, Nordenskjöld M, Sundström C, Enblad G, Dalla-Favera R, Zhang H, Teixeira M, **Pasqualucci L**, Peng R, Pan-Hammarström Q. Genetic basis of PD-L1 overexpression in diffuse large b cell lymphoma. *Blood*, 2016; *in press*.
2. Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, Vlasevska S, Mo T, Tang H, Basso K, Ge K, Dalla-Favera R, **Pasqualucci L**. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. *Nat Med* 2015; 21(10): 1190-1198.
3. Zhang B, Calado DP, Wang Z, Fröhler S, Köchert K, Qian Y, Koralov SB, Schmidt-Suppran M, Sasaki Y, Unitt C, Rodig S, Chen W, Dalla-Favera R, Alt FW, **Pasqualucci L***, Rajewsky K*. An oncogenic role for alternative NF- κ B signaling in DLBCL revealed upon deregulated BCL6 expression. *Cell Reports* 11(5):715-726, 2015. PMID: 25921526 (*equal contribution)
4. Nakagawa MM, Thummar K, Mandelbaum J, **Pasqualucci L**, Rathinam CV. Lack of the ubiquitin-editing enzyme A20 results in loss of hematopoietic stem cell quiescence. *J Exp Med* 212(2):203-16, 2015.
5. Messina M, Del Giudice I, Khiabani H, Rossi D, Chiaretti S, Rasi S, Spina V, Holmes AB, Marinelli M, Fabbri G, Piciocchi A, Mauro FR, Guarini A, Gaidano G, Dalla-Favera R, **Pasqualucci L**, Rabadan R, Foà R. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. *Blood*, 2014; 123(15): 2378-2388. PMID: 24550227.
6. **Pasqualucci L***, Khiabani H, Fangazio M, Vasishtha M, Messina M, Holmes AB, Ouillette P, Trifonov V, Rossi D, Tabbò F, Ponzoni M, Chadburn A, Murty VV, Bhagat G, Gaidano G, Inghirami G, Malek SN, Rabadan R, Dalla-Favera R*. Genetics of Follicular Lymphoma Transformation. *Cell Reports*, 2014; 6(1): 130-140. PMCID: PMC4100800. (Corresponding Author)
7. Burkhard R, Bhagat G, Cogliatti SB, Rossi D, Gaidano G, **Pasqualucci L**, Novak U. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. *Hematological Oncology*, 2014. PMID: 24496723.
8. Wang J, Khiabani H, Rossi D, Fabbri G, Gattei V, Forconi F, Laurenti L, Marasca R, Del Poeta G, Foà R, **Pasqualucci L**, Gaidano G, Rabadan R. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. *Elife*, 2014;3.
9. Fabbri G, Khiabani H, Holmes AB, Wang J, Messina M, Mullighan CG, **Pasqualucci L**, Rabadan R, Dalla-Favera R. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter Syndrome. *J Exp Med*, 2013; 210(11): 2273-2288. PMCID: PMC3804949

10. Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC, Hussein S, Bansal M, Califano A, **Pasqualucci L**, Basso K, Dalla-Favera R. MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma. *Nature Immunology*, 2013; 14(10):1084-1092.
11. Trifonov V, **Pasqualucci L**, Tiacci E, Falini B, Rabadan R. SAVI: a statistical algorithm for variant frequency identification. *BMC Systems Biology*, 2013; 7(2): 1-11.
12. Trifonov V, **Pasqualucci L**, Dalla-Favera R, Rabadan R. MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. *BMC Syst Biol*, 2013; 7:25-33.
13. Rossi D, Rasi S, Spina V, Bruscazzin A, Monti S, Ciardullo C, Deambrogi C, Khiabani H, Serra R, Bertoni F, Forconi F, Laurenti L, Marasca R, Dal-Bo M, Rossi FM, Bulian P, Nomdedeu J, Del Poeta G, Gattei V, **Pasqualucci L**, Rabadan R, Foà R, Dalla-Favera R, Gaidano G. Integrated mutational and cytogenetic analysis identified new prognostic subgroups in chronic lymphocytic leukemia. *Blood*, 2013; 121(8):1403-12.
14. Peifer M, Fernández-Cuesta L, Sos M, George J, Seidel D, Kasper L, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus H-U, Altmueller J, Baessmann I, Becker C, De-Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann J, Lu X, Cibulskis C, Banerji S, Getz G, Park K-S, Rauh D, Grütter C, Fischer F, **Pasqualucci L**, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella L, Fazio V, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Snijders P, Cappuzzo F, Ligorio L, Damiani S, Field J, Prof. Steinar Solberg, Brustugun OT, Lund-Iversen M, Sängler J, Clement J, Soltermann A, Moch H, Weder W, Solomon B, Soria J-C, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider P, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nurnberg P, Perner S, Heukamp L, Brindle P, Haas S, Carter S, Thomas R. Integrative genome analyses identify key somatic driver mutations of small cell lung cancer. *Nature Genetics*, 2012; 44(10):1104-1110.
15. Rossi D, Trifonov V, Fangazio M, Bruscazzin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R*, **Pasqualucci L***, Rabadan R*, Gaidano G*. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. *J Exp Med*, 2012; 209(9); 1537-51. (*corresponding authors)
16. **Pasqualucci L***, Dominguez-Sola D, Chiarenza A, Fabbri A, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK and Dalla-Favera R*. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature*, 2011; 471(7337):189-195. (*corresponding authors)
17. Trifonov V, **Pasqualucci L**, Dalla-Favera R, Rabadan R. Fractal-like distributions over the rational numbers in high-throughput biological and clinical data. *Sci Rep*, 2012; 1:191.

18. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscazzin A, Spina V, Deambrogi C, Marinelli M, Famà R, Greco M, Daniele G, Forconi F, Gattei V, Bertoni F, Deaglio S, **Pasqualucci L**, Guarini A, Dalla-Favera R, Foà R, Gaidano G. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia. *Blood*, 2012; 119(12): 2854-2862.
19. Challa-Malladi M, Lieu YK, Califano O, Holmes A, Bhagat G, Murty VV, Dominguez-Sola D, **Pasqualucci L***, Dalla-Favera R*. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. *Cancer Cell*, 2011; 20(6): 728-740. (*equal contribution)
20. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscazzin A, Cerri M, Monti S, Cresta S, Famà R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, **Pasqualucci L**, Dalla-Favera R, Foà R, Gaidano G. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. *Blood*, 2011; 119(2): 521-529.
21. Rossi D, Bruscazzin A, Spina V, Rasi S, Khiabani H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, Guarini A, Del Giudice I, Cerri M, Cresta S, Deambrogi C, Gargiulo E, Gattei V, Forconi F, Bertoni F, Deaglio S, Rabadan R, **Pasqualucci L**, Foà R, Dalla-Favera R, Gaidano G. Blood. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. *Blood*, 2011; 118(26): 6904-6908.
22. Tiacci E, Spanhol-Rosseto A, Martelli MP, **Pasqualucci L**, Quentmeier H, Grossmann V, Drexler HG, Falini B. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations. *Leukemia*, 2011.
23. Grossmann V, Tiacci E, Holmes A, Kohlmann A, Martelli MP, Kern W, Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S, Haferlach C, Bassan^R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A, **Pasqualucci L**, Rabadan R, Haferlach T, Falini B. Whole-exome sequencing identifies mutations of BCOR in acute myeloid leukemia with normal karyotype. *Blood*, 2011; 118(23): 6153-6163.
24. Novak U, Basso K, **Pasqualucci L**, Dalla-Favera R, Bhagat G. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. *Br J Haematol*, 2011; 155(3):362-365.
25. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, Spina V, Bruscazzin A, Monti S, Cerri M, Cresta S, Fangazio M, Arcaini L, Lucioni M, Marasca R, Thieblemont C, Capello D, Facchetti F, Kwee I, Pileri SA, Foà R, Bertoni F, Dalla-Favera R, **Pasqualucci L**, Gaidano G. Alterations of *BIRC3* and multiple other NF- κ B pathway genes in splenic marginal zone lymphoma. *Blood*, 2011; 118(18):4930-4934.
26. **Pasqualucci L***, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R*. Analysis of the coding genome of diffuse large B cell lymphoma. *Nature Genetics*, 2011; 43:830-837, 2011. (*corresponding authors)

27. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabani H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscieri D, Bertoni F, Mullighan CG, Foa' R, **Pasqualucci L***, Rabadan R*, Dalla-Favera R*, Gaidano G*. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med*, 2011; 208(7):1389-1401. (*equal contribution)
28. Tiacci E, Trifonov V, Schiavoni G, Holmes AB, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells V, Sportoletti P, Pettrossi V, Mannucci R, Elliot O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foa' R, Farinelli L, Haferlach T, **Pasqualucci L**, Rabadan R, Falini B. *BRAF* mutations in Hairy Cell Leukemia, *N Engl J Med*, 2011; 364(24):2305-2315.
29. Green MR, Monti S, Dalla-Favera R, **Pasqualucci L**, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. *Proc Natl Acad Sci USA*, 2011; 108(7):2873-8.
30. Mandelbaum J, Bhagat G, Tang H, Mo T, Grunn A, Brahmachary M, Shen Q, Chadburn A, Rajewsky K, Tarakhovskiy A, **Pasqualucci L***, Dalla-Favera R*. Blimp1 is a tumor suppressor gene frequently disrupted in activated B-cell like diffuse large B cell lymphoma. *Cancer Cell*, 2010; 18(6):568-579. (*equal contribution)
31. Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, Dalla-Favera R, **Pasqualucci L***, MacLennan AJ*. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. *Cancer Research*, 2009; 69(22):8686-8692. (*co-corresponding authors)
32. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, Crespo M, Bhagat G, Califano A, Chadburn A, **Pasqualucci L**, Dalla-Favera R. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. *Proc Natl Acad Sci USA*, 2009; 106(27):11294-11299.
33. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, **Pasqualucci L**. Mutations in multiple genes cause deregulation of the NF- κ B pathway in diffuse large B-cell lymphoma. *Nature*, 2009; 459(7247):717-721.
34. Novak U, Rinadi A, Kwee I, Nandula SV, Rancoita PMV, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, **Pasqualucci L**, Bhagat G, Bertoni F. The NF- κ B negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. *Blood*, 2009; 13(20):4918-4921.
35. Vakiani E, Basso K, Klein U, Mansukhani NM, Narayan G, Smith PM, Murty VV, Dalla-Favera R, **Pasqualucci L**, Bhagat G. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. *Hematol Oncol*, 2008; 26(4): 199-211.

36. **Pasqualucci L**, Li S, Meloni G, Schnittger S, Gattenlohner S, Liso A, Di Ianni M, Martelli MP, Pescarmona E, Foa R, Haferlach T, Skoda RC, Falini B. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? *Leukemia*, 2008; 22(7):1459-1463.
37. **Pasqualucci L***, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, Honjo T, Morse HC 3rd, Nussenzweig MC, Dalla-Favera R*. AID is required for germinal center-derived lymphomagenesis. *Nature Genetics*, 2008; 40:108-112. (*corresponding authors).
38. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, Pernis A, **Pasqualucci L**, Dalla-Favera R. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. *Cancer Cell*, 2007; 12: 280-292.
39. Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, Lunghi M, Conconi A, Paulli M, Matolcsy A, **Pasqualucci L**, Capello D, Gaidano G. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. *Haematologica*, 2006; 91:1405-1409.
40. **Pasqualucci L**, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A, Carini M, Bigerna B, Pucciarini A, Mannucci R, Nicoletti I, Tiacci E, Meloni G, Specchia G, Cantore G, Di Raimondo F, Pileri A, Mecucci C, Mandelli F, Martelli MF, and Falini B. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. *Blood*, 2006; 108: 4146-4155.
41. Liso A, Capello D, Marafioti T, Tiacci E, Cerri M, Distler V, Paulli M, Carbone A, Del Sol G, Campo E, Pileri S, **Pasqualucci L**, Gaidano G and Falini B. Aberrant somatic hypermutation in nodular lymphocyte-predominant and classical Hodgkin's lymphoma. *Blood*, 2006; 108: 1013-1020.
42. **Pasqualucci L**, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, and Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 Gene in Diffuse Large B-cell Lymphoma. *J Exp Med*, 2006; 203: 311-317.
43. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, Bigerna B, **Pasqualucci L**, Mannucci R, Rosati R, Gorello P, Diverio D, Roti G, Tiacci E, Cazzaniga G, Biondi A, Schnittger S, Haferlach T, Hiddemann W, Martelli MF, Gu W, Mecucci C, Nicoletti I. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. *Blood*, 2006; 107: 4514-4523.
44. **Pasqualucci L***, Kitaura Y, Gu H, Dalla-Favera R. PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. *Proc Natl Acad Sci USA*, 2006; 103: 395-400. (*corresponding author)
45. Rossi D, Cerri M, Capello D, Deambrogi C, Berra E, Franceschetti S, Alabisio O, Gloghini A, Paulli M, Carbone A, Pileri SA, **Pasqualucci L**, Gaidano G. Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. *Leukemia*, 2005; 19: 2363-2366.

46. Winkler D, Schneider C, Krober A, **Pasqualucci L**, Lichter P, Dohner H, Stilgenbauer S. Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL). *Leukemia*, 2005; 19: 1211-1215.
47. Cattoretti G*, **Pasqualucci L***, Ballon G, Tam W, Nandula SN, Shen Q, Mo T, Murty VV, Dalla-Favera R. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B-cell lymphomas in mice. *Cancer Cell*, 2005; 7:445-455. (*equal contribution)
48. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, **Pasqualucci L**, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood*, 2005; 105(5):1851-1861.
49. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, **Pasqualucci L**, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. *N Engl J Med*, 2005; 352(3): 254-66.
50. Libra M, Capello D, Gloghini A, **Pasqualucci L**, Berra E, Cerri M, Gasparotto D, Franca S, De Re V, Gaidano G, Carbone A. Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. *J Pathol*, 2005; 206(1):87-91.
51. Cerri M, Capello D, Muti G, Rambaldi A, Paulli M, Gloghini A, Berra E, Deambrogi C, Rossi D, Franceschetti S, Conconi A, Morra E, **Pasqualucci L**, Carbone A, Gaidano G. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders. *Br J Haematol*, 2004; 127(3):362-364.
52. **Pasqualucci L***, Guglielmino R, Houldsworth J, Mohr J, Reynaud CA, Polakiewicz R, Chaganti RSK, Dalla-Favera R. Expression of the AID protein in normal and neoplastic B cells. *Blood*, 2004; 104(10):3318-3325.(*corresponding author)
53. Falini B, Tiacci E, Pucciarini A, Bigerna B, Kurth J, Hatzivassiliou G, Droetto S, Galletti BV, Gambacorta M, Orazi A, **Pasqualucci L**, Miller I, Küppers R, Dalla-Favera R, Cattoretti G. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). *Blood*, 2003; 102(10): 3684-3692.
54. Gaidano G, **Pasqualucci L**, Capello D, Berra E, Deambrogi C, Rossi D, Larocca LM, Gloghini A, Carbone A, Dalla-Favera R. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. *Blood*, 2003; 102(5): 1833-1841.
55. **Pasqualucci L**, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood*, 2003; 101(8): 2914-2923.
56. **Pasqualucci L**, Migliazza A, Ye HB, Dalla-Favera R. Transcriptional Deregulation of Mutated BCL6 Alleles by Loss of Negative Autoregulation in Diffuse Large B Cell Lymphoma. *Am. N.Y. Acad. Sci*, 2003; 987(49):314-316.

57. **Pasqualucci L**, Neumeister P, Goossens T, Nanjangud G, Chaganti RSK, Küppers R, Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell Diffuse Large Cell Lymphomas *Nature*, 2001; 412: 341-346.
58. **Pasqualucci L**, Neri A, Baldini L, Dalla-Favera R, Migliazza A. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. *Cancer Res*, 2000; 60 (20): 5644-5648.
59. Capello D, Vitolo U, **Pasqualucci L**, Quattrone S, Migliaretti G, Fassone L, Ariatti C, Vivenza D, Gloghini A, Pastore C, Lanza C, Nomdedeu J, Botto B, Freilone R, Buonaiuto D, Zagonel V, Gallo E, Palestro G, Saglio G, Dalla-Favera R, Carbone A, Gaidano G. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. *Blood*, 2000; 95(2): 651-659.
60. **Pasqualucci L**, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti RSK, Klein U, Kuppers R, Rajewsky K, Dalla-Favera R. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci USA*, 1998; 95 (20): 11816-11821.
61. Qu X-Y, Hauptschein RS, Rzhetsky, Scotto L, Chien M-C, Ye X, Frigeri F, Rao PH, **Pasqualucci L**, Gamberi B, Deaven LL, Zhang P, Chaganti RSK, Dalla-Favera R, Russo JJ. Analysis of a 69-kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27. *DNA Sequence*, 1998; 9 (4): 189-204.
62. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Lemoli R, Terenzi A, **Pasqualucci L**, Falini B, Stirpe F. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. *Br J Haematol*, 1998; 101(1): 179-188.
63. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, **Pasqualucci L**, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). *Blood*, 1997; 90: 4046-4053.
64. Falini B, Liso A, **Pasqualucci L**, Flenghi L, Ascani S, Pileri S, Bucciarelli E. CD30+ anaplastic large-cell lymphoma, null type, with signet-ring appearance. *Histopathology*, 1997; 30: 90-92.
65. Falini B, Bigerna B, **Pasqualucci L**, Fizzotti M, Martelli MF, Pileri S, Pinto A, Carbone A, Venturi S, Pacini R, Cattoretti G, Pescarmona E, Lo Coco F, Pelicci PG, Anagnostopoulos I, Dalla-Favera R, Flenghi L. Distinctive expression pattern of the Bcl-6 protein in nodular lymphocyte predominance Hodgkin's disease. *Blood*, 1996; 87: 465-471.
66. Flenghi L, Bigerna B, Fizzotti M, Venturi S, **Pasqualucci L**, Pileri S, Ye BH, Gambacorta M, Pacini R, Baroni CD, Pescarmona E, Anagnostopoulos I, Stein H, Asdrubali G, Martelli MF, Pelicci PG, Dalla-Favera R, Falini B. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. *Am J Pathol*, 1996; 148(5): 1543-1555.

67. Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B, Pacini R, Tanci LN, **Pasqualucci L**, Ascani S, Mencarelli A, Liso A, Pelicci PG, Falini B. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. *Am J Pathol*, 1996; 149: 2023-1035.
68. Terenzi A, Bolognesi A, **Pasqualucci L**, Flenghi L, Pileri S, Stein H, Kadin ME, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B. Anti-CD30 (BER-H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumor activity against CD30+ tumour cells in vitro and in SCID mice. *Br J Haematol*, 1996; 92(4): 872-879.
69. **Pasqualucci L**, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin ME. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/Saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. *Blood*, 1995; 85: 2139-2146.
70. Falini B, Venturi S, Martelli MF, Santucci A, Pileri S, Pescarmona E, Giovannini M, Mazza P, Martelli MF, **Pasqualucci L**, Ballatori E, Guglielmi C, Amadori S, Poggi S, Sabattini E, Gherlinzoni F, Zinzani PL, Baroni CD, Mandelli F, Tura S. Mediastinal large B-cell lymphoma: clinical and immunohistologic findings in 18 patients treated with different third-generation regimens. *Br J Haematol*, 1995; 89: 780-789.
71. Comparison of immunosuppressive effects of single-dose and hyperfractionated total body irradiation. *Transplant Proc*, 1994; 26: 3217.

Books and Chapters:

1. **Pasqualucci L**. Diffuse Large B cell Lymphoma. G. Lenz and L Pasqualucci (eds). In: *Malignant Lymphomas. Biology and Molecular Pathogenesis*, De Gruyter GmbH (publ.) Berlin/Boston, 2016.
2. Fangazio M, Pasqualucci L and Dalla-Favera R. Chromosomal Translocations in B cell Lymphomas. JD Rowley, MM Le Beau and TH Rabbits (eds). In: *Chromosomal Translocations and Genome Rearrangements in Cancer*. Springer International Publishing Switaerland (publ.), Heidelberg/New York 2015
3. **Pasqualucci L** and Dalla-Favera R. Molecular Biology of Lymphoma. VT DeVita, Jr., TS Lawrence, and SA Rosenberg (eds). In: *DeVita, Hellman, and Rosenberg's. Cancer: Principles and Practices of Oncology*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2015.
4. Dalla-Favera R and **Pasqualucci L**. Molecular Pathogenesis of B Cell Lymphomas. Honjo T, Reth M, Radbruch A and Alt FW(ed). In: *Molecular Biology of B cells, 2nd Edition*, Elsevier (publ.), 2014. ISBN 978-0-1239-7933-9.
5. Schneider C, **Pasqualucci L**, Dalla-Favera R. Molecular Pathology of Lymphoma. GELMANN, SAWYERS & RAUSCHER (eds). In *Molecular Oncology*, Cambridge University Press, Cambridge UK, 2014. ISBN: 9780521876629.

6. **Pasqualucci L** and Tam, W. Proto-oncogenes and Tumor Suppressor Genes in Hematopoietic Malignancies. A Orazi, L Weiss, K Foucar, DM Knowles (eds). In: *Knowles' Neoplastic Hematopathology*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2013.
7. **Pasqualucci L**. Diffuse large B cell lymphoma. E. S. Robertson (ed.). In: *Burkitt's Lymphoma*, Springer Press (publ.) New York, 2013: 151-173. ISBN 978-1-4614-4313-1.
8. Novak U, **Pasqualucci L** and Dalla-Favera R. Molecular Biology of Lymphoma. VT. DeVita, Jr., TS Lawrence, and SA Rosenberg (eds). In: *DeVita, Hellman, and Rosenberg's. Cancer: Principles and Practices of Oncology*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2011.
9. Dalla-Favera R and **Pasqualucci L**. Molecular Genetics of Lymphoma. PM Mauch, JO Armitage, B Coiffier, R Dalla-Favera, NL Harris (eds.). In: *Non-Hodgkin's Lymphomas, 2nd Edition*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2010: 115-129. ISBN 978-0-7817-9116-8.
10. Dalla-Favera R and **Pasqualucci L**. Molecular Genetics of Lymphoma. PM Mauch, JO Armitage, B Coiffier, R Dalla-Favera, NL Harris (eds.). In: *Non-Hodgkin's Lymphomas*, Lippincott Williams and Wilkins (publ.) Philadelphia, 2004: 825-843.
11. Falini B, Terenzi A, Liso A, Flenghi L, Solinas A, **Pasqualucci L**. Targeted Antibodies in the Treatment of Lymphomas. J Tooze and A.C. Wotherspoon (eds.). In: *Cancer Surveys, Vol 30: Lymphoma*. Cold Spring harbor Laboratory Press (publ.) 1997: 295-309.
12. Flenghi L, **Pasqualucci L**, Bigerna B, Pacini R, Natali-Tanci L, Venturi S, Pileri S, Falini B. Linfoma/Leucemia dei precursori linfoidi. In: *Linfomi non-Hodgkin*, attualita' di diagnosi e terapia, Seminari di Ematologia, Vol 1, 1995.

Reviews and Editorials

1. **Pasqualucci L** and Dalla-Favera R. The genetic landscape of diffuse large B cell lymphoma. *Semin Hematol*, 2015: 52(2), 67-76. PMID: 25805586
2. **Pasqualucci L** and Dalla-Favera R. SnapShot: Diffuse Large B Cell Lymphoma. *Cancer Cell*, 2014: 25(1), 132.
3. **Pasqualucci L**. The genetic basis of diffuse large B-cell lymphoma. *Curr Opin Hematol*, 2013; 20(4): 336-44.
4. Schneider C, **Pasqualucci L**, Dalla-Favera R. Molecular Pathogenesis of diffuse large B-cell lymphoma. *Semin Diagn Pathol*, 2011; 28(2):167-177.
5. **Pasqualucci L**. Relevant Pathogenetic Pathways in Diffuse Large B cell Lymphoma. *16th Congress of the European Hematology Association, Education Session on Diffuse Large B cell Lymphoma* 2011.
6. Klein U, **Pasqualucci L**. B cell receptor signaling derailed in lymphomas. *Immunol Cell Biol*, 2010; 88(4):346-347.

7. Cancer Target Discovery and Development Network, Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, Lowe SW, Guo X, Krasnitz A, Sawey ET, Sordella R, Stein L, Trotman LC, Califano A, Dalla-Favera R, Ferrando A, Iavarone A, **Pasqualucci L**, Silva J, Stockwell BR, Hahn WC, Chin L, DePinho RA, Boehm JS, Gopal S, Huang A, Root DE, Weir BA, Gerhard DS, Zenklusen JC, Roth MG, White MA, Minna JD, MacMillan JB, Posner BA. Towards patient-based cancer therapeutics. *Nat Biotechnol*, 2010; 28: 904-906.
8. Heerema NA, Bernheim A, Lim MS, Look AT, **Pasqualucci L**, Raetz E, Sanger WG, Cairo MS. State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: Summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. *Pediatr Blood Cancer*, 2005; 45(5):616-22.
9. **Pasqualucci L**, Bereschenko O, Niu H, Klein U, Basso K, Guglielmino R, Cattoretto G, and Dalla-Favera R. Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the role of BCL6. *Leukemia & Lymphoma*, 2003, 69:927-931.
10. Harris NL, Stein H, Coupland SE, Hummel M, Dalla-Favera R, **Pasqualucci L**, Chan WC. New approaches to lymphoma diagnosis. *Hematology* (Am Soc Hematol Educ Program), 2001; 194-220.
11. Dalla-Favera R, Migliazza A, Chang CC, Niu H, **Pasqualucci L**, Butler M, Shen Q, Cattoretto G. Molecular pathogenesis of B cell malignancy: the role of BCL-6. *Curr Top Microbiol Immunol*, 1999; 246:257-263.
12. Gaidano G, Capello D, Gloghini A, Pastore C, Migliazza A, Quattrone S, Savinelli F, Buonaiuto D, Cilia AM, Perin T, **Pasqualucci L**, Canzonieri V, Saglio G, Dalla-Favera R, Carbone A. BCL-6 in AIDS-related lymphomas: pathogenetic and histogenetic implications. *Leukemia and Lymphoma*, 1998; 31(1-2): 39-46.
13. Falini B, Fizzotti M, Pileri S, Liso A, **Pasqualucci L**, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. *Ann Oncol*, 1997; 8, Suppl 2: 101-104.
14. **Pasqualucci L**, Flenghi L, Terenzi A, Bolognesi A, Stirpe F, Falini B: Immunotoxin therapy of hematopoietic malignancies. *Hematologica* 1995; 80: 551-559.
15. Falini B, Flenghi L, **Pasqualucci L**, Martelli MF, Venturi S, Scarpelli N, Blass A, Stirpe F, Pileri S, Martelli MF. Gli anticorpi monoclonali nella terapia delle emopatie maligne. *Hematologica*, 1993.